. 2010 May 29;34(9):2090–2097. doi: 10.1007/s00268-010-0639-5

Table 2.

Clinical data and tumor characteristics in high risk historical controls

Patients	Tumor site	Tumor size (cm)^a	Ki67 (max%)^a	Receptor tyrosine kinase mutations	Follow-up (months)^a
No.: 89 Sex (F/M: 45:44)	Stomach: 43 Duodenum: 4 Small bowel: 33 Large bowel: 5 Rectum: 4	14.4 ± 8.0 (5–35)	15.0 ± 14.4 (0.5–50)	KIT exon 11 Del: 41 Miss: 9 Dupl: 6	KIT exon 9: n = 2	PDGFRA exon 18: n = 0	PDGFRA exon 12: n = 1	WT: n = 30	39.2 ± 4.9 (2–233)

Patients

Tumor site

Tumor size (cm)^a

Ki67 (max%)^a

Receptor tyrosine kinase mutations

Follow-up (months)^a

No.: 89

Sex (F/M: 45:44)

Stomach: 43

Duodenum: 4

Small bowel: 33

Large bowel: 5

Rectum: 4

14.4 ± 8.0 (5–35)

15.0 ± 14.4 (0.5–50)

KIT exon 11

Del: 41

Miss: 9

Dupl: 6

KIT exon 9: n = 2

PDGFRA exon 18: n = 0

PDGFRA exon 12: n = 1

WT: n = 30

39.2 ± 4.9 (2–233)

Del deletion, dupl duplication, Miss missense mutation, PDGFRA platelet-derived growth factor receptor α, WT wild type (in KIT and PDGFRA)

^aMean ± SD and range